Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors

Exp Hematol. 1999 Sep;27(9):1384-96. doi: 10.1016/s0301-472x(99)00084-3.

Abstract

Abnormal circulation and unregulated proliferation of chronic myelogenous leukemia (CML) progenitors is related, at least in part, to BCR/ABL induced abnormalities in beta1 integrin-mediated adhesion and signaling. The BCR/ABL oncogene has several potential interactions with cytoskeletal elements that are important for normal integrin signaling. In the present study, we evaluated whether abnormalities in beta1 integrin-cytoskeletal interactions were present in primary CML progenitors and contributed to defective integrin function. beta1 integrin-cytoskeletal interactions were studied in CML and normal CD34+ primary hematopoietic progenitors as well as BCR/ABL-transfected or mock-transfected M07e cells. In normal CD34+ progenitors, antibody-mediated cross-linking of beta1 integrins resulted in their redistribution into caps via a process requiring receptor-cytoskeletal interactions. CML CD34+ cells demonstrated significantly impaired beta1 integrin capping. This defect was related to the presence of the BCR/ABL gene, because capping also was impaired in BCR/ABL-transfected M07e cells. Defective receptor capping was not seen for non-integrin receptors. In addition, CML CD34- and M07eBCR/ABL cells also demonstrated increased actin polymerization and altered actin cytoskeletal organization. Further studies suggested that impaired beta1 integrin capping and defective integrin-mediated adhesion and proliferation inhibition in CML cells were related to abnormally enhanced integrin-cytoskeletal association and restricted receptor mobility. Finally, interferon alpha, which restores integrin-mediated adhesion and signaling in CML progenitors, also enhanced integrin capping in CD34+ cells. These studies suggest that p210BCR/ABL induces abnormal association of integrin receptors with the cytoskeleton and restricted receptor mobility and provide new insights into mechanisms underlying abnormal integrin function in CML progenitors.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Actins / analysis
  • Cell Adhesion / drug effects
  • Cell Division
  • Cell Membrane / ultrastructure
  • Cells, Cultured
  • Cytochalasin D / pharmacology
  • Cytoskeleton / chemistry
  • Cytoskeleton / drug effects
  • Cytoskeleton / pathology*
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / physiology
  • Hematopoietic Stem Cells / chemistry
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Integrin beta1 / physiology*
  • Interferon alpha-2
  • Interferon-alpha / pharmacology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Neoplastic Stem Cells / chemistry
  • Neoplastic Stem Cells / pathology*
  • Receptor Aggregation*
  • Recombinant Proteins
  • Transfection
  • Tumor Cells, Cultured

Substances

  • Actins
  • Integrin beta1
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Cytochalasin D
  • Fusion Proteins, bcr-abl